Ma G, et al. - Researchers compared outcomes of patients with autoimmune diseases vs those without autoimmune disease following percutaneous coronary intervention (PCI) by analyzing data from studies addressing this topic. These studies were identified from Medline, EMBASE, and the Cochrane Library, and were focused on long-term mortality, major adverse cardiovascular events (MACE), repeat revascularization, myocardial ischemia or myocardial infarction (MI), restenosis, and in-hospital mortality. According to very low-quality evidence, the likelihood of experiencing MACEs, repeat revascularization, myocardial ischemia or MI, and restenosis during the one-year follow-up period was greater in patients with autoimmune diseases after PCI. Death was more likely to be reported in patients with autoimmune diseases after PCI during the 11-year follow up. Careful monitoring of these adverse cardiovascular events was considered important in patients with autoimmune diseases after PCI.